Hemophilia B gene therapy with a high-specific-activity factor IX variant
Key findings
Spark100 is a bioengineered AAV capsid derived from AAVrh.74. Designed for efficient liver transduction with low pre-existing neutralizing antibodies in human population. Used in SPK-9001 hemophilia B clinical trials demonstrating sustained factor IX expression.